Table 3.
comorbidities and medicine use history among the COVID-19 patients admitted to Mengo Hospital Treatment Unit from December 2020 to August 2021 (N=314)
| Variable | Yes, n (%) |
|---|---|
| Comorbidity | |
| Diabetes | 104 (33.1) |
| Hypertension | 144 (45.8) |
| Coronary heart disease | 25 (8.0) |
| Chronic liver disease | 2 (0.6) |
| Chronic kidney disease | 4 (1.3) |
| Stroke | 13 (4.1) |
| HIV/AIDS | 17 (5.4) |
| Cancer | 8 (2.6) |
| Medicine | |
| Dexamethasone | 139 (44.3) |
| Metformin monotherapy | 38 (12.1) |
| Metformin + sulphonyl urea | 26 (8.3) |
| Insulin monotherapy | 39 (12.4) |
| Insulin + oral hypoglycemics | 12 (3.8) |
| Lipid-lowering agents | 72 (22.9) |
| Anti - hypertensives | 140 (44.6) |
| ARV | 16 (5.1) |
n: frequency; HIV: human immunodeficiency virus; AIDS: acquired immune deficiency syndrome, ARV: antiretroviral drugs